AptarGroup's Q3 2024 results showed a 2% increase in both reported and core sales, driven by the Pharma and Closures segments. Net income increased by 19% to $100 million, and adjusted EPS rose by 6% to $1.49.
Reported and core sales increased by 2%.
Reported EPS increased 17% to $1.48, and adjusted EPS increased 6% to $1.49.
Reported net income increased 19% to $100 million.
Pharma segment delivered reported sales growth of 8% and core sales growth of 7%.
Aptar anticipates a solid finish to a strong year, with top-line growth expected in Q4 despite some customer inventory adjustments. Pharma is expected to finish within its core sales long-term target range, and Closures expects a strong finish with healthy margin improvements. Beauty continues to focus on the bottom line in a tough macro environment.
Visualization of income flow from segment revenue to net income